Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zuranolone (SAGE-217) in MDD with Comorbid Insomnia
NCT03771664Phase 3Terminated
- Sponsor
- Biogen
- Start
- Feb 2019
- Primary completion
- Dec 2019
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) and Insomnia comparing Placebo with SAGE-217 (2 arms). Primary endpoint: Average Change From Baseline in Sleep Efficiency (SE) as Assessed by Polysomnogram (PSG) at Day 14. Started Feb 2019; status: terminated.
02
Drugs
zuranolone
03
Conditions
major depressive disorder (MDD)Insomnia
Beyond the preview
Go deeper on NCT03771664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03771664.